Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Dose Escalating Study to Evaluate the Safety, Tolerability, Anti-Tumour Activity and Pharmacokinetic and Pharmacodynamic Profiles of Foxy-5 in Patients With Metastatic Breast, Colon or Prostate Cancer

NCT02020291 is registered in ClinicalTrials.gov with WntResearch AB as lead sponsor.

NCT NCT02020291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02020291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Dose Escalating Study to Evaluate the Safety, Tolerability, Anti-Tumour Activity and Pharmacokinetic and Pharmacodynamic Profiles of Foxy-5 in Patients With Metastatic Breast, Colon or Prostate Cancer
Lead sponsor
WntResearch AB
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2013
Completion date
November 30, 2015
Enrollment
31 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, metastatic breast cancer, prostate cancer